Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to $30.8 million.

  • Standard Biotools' Accumulated Expenses fell 276.46% to $30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.8 million, marking a year-over-year decrease of 276.46%. This contributed to the annual value of $21.4 million for FY2024, which is 197.92% up from last year.
  • As of Q3 2025, Standard Biotools' Accumulated Expenses stood at $30.8 million, which was down 276.46% from $24.2 million recorded in Q2 2025.
  • Standard Biotools' 5-year Accumulated Expenses high stood at $31.9 million for Q2 2024, and its period low was $8.0 million during Q1 2022.
  • Over the past 5 years, Standard Biotools' median Accumulated Expenses value was $10.6 million (recorded in 2022), while the average stood at $16.8 million.
  • Per our database at Business Quant, Standard Biotools' Accumulated Expenses tumbled by 4703.73% in 2022 and then surged by 26097.27% in 2024.
  • Over the past 5 years, Standard Biotools' Accumulated Expenses (Quarter) stood at $8.7 million in 2021, then increased by 5.53% to $9.2 million in 2022, then skyrocketed by 129.64% to $21.0 million in 2023, then increased by 1.98% to $21.4 million in 2024, then soared by 43.74% to $30.8 million in 2025.
  • Its Accumulated Expenses stands at $30.8 million for Q3 2025, versus $24.2 million for Q2 2025 and $22.0 million for Q1 2025.